|
US5929549A
(en)
*
|
1998-04-02 |
1999-07-27 |
Pacific Scientific Company |
Fault tolerant electric machine
|
|
US6437529B1
(en)
|
1998-05-04 |
2002-08-20 |
Comair Rotron, Inc. |
Multi-stator motor with independent stator circuits
|
|
DE19856647B4
(en)
*
|
1998-12-09 |
2007-03-01 |
Canders, Wolf-R., Prof. Dr.-Ing. |
Electric high-torque motor
|
|
EP1262687B1
(en)
*
|
2001-06-01 |
2009-03-25 |
IHI Aerospace Co., Ltd. |
Electromotive actuator and method for controlling the same
|
|
DE60215095T2
(en)
*
|
2001-09-19 |
2007-05-10 |
Parker-Hannifin Corp., Cleveland |
Motor drive and system
|
|
US6819017B2
(en)
|
2002-01-02 |
2004-11-16 |
Intel Corporation |
Method and apparatus for fan redundancy
|
|
US6700266B2
(en)
*
|
2002-01-02 |
2004-03-02 |
Intel Corporation |
Multiple fault redundant motor
|
|
US6724183B2
(en)
|
2002-01-02 |
2004-04-20 |
Intel Corporation |
Method and apparatus for detecting bearing failure
|
|
US6791209B2
(en)
|
2002-01-02 |
2004-09-14 |
Intel Corporation |
Power and control for power supply fans
|
|
US7583063B2
(en)
|
2003-05-27 |
2009-09-01 |
Pratt & Whitney Canada Corp. |
Architecture for electric machine
|
|
EP2505649A1
(en)
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of GCGR
|
|
ES2386578T3
(en)
|
2006-05-05 |
2012-08-23 |
Isis Pharmaceuticals, Inc. |
Compounds and procedures to modulate PCSK9 expression
|
|
US7443642B2
(en)
|
2006-05-26 |
2008-10-28 |
Pratt & Whitney Canada Corp. |
Electric motor control
|
|
GB0613941D0
(en)
|
2006-07-13 |
2006-08-23 |
Pml Flightlink Ltd |
Electronically controlled motors
|
|
DK2410054T4
(en)
|
2006-10-18 |
2020-02-10 |
Ionis Pharmaceuticals Inc |
Antisense Compounds
|
|
US7605503B2
(en)
|
2007-03-28 |
2009-10-20 |
General Electric Company |
Fault-tolerant permanent magnet machine with reconfigurable stator core slot opening and back iron flux paths
|
|
US7605504B2
(en)
|
2007-03-28 |
2009-10-20 |
General Electric Company |
Fault-tolerant permanent magnet machine with reconfigurable stator core slot flux paths
|
|
US7541705B2
(en)
|
2007-03-28 |
2009-06-02 |
General Electric Company |
Fault-tolerant permanent magnet machine with reconfigurable flux paths in stator back iron
|
|
US8222221B2
(en)
|
2008-06-04 |
2012-07-17 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small RNA targeting of gene promoters
|
|
JP2011529686A
(en)
|
2008-07-29 |
2011-12-15 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
Selective inhibition of polyglutamine protein expression
|
|
EP2447274B1
(en)
|
2008-10-24 |
2017-10-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
|
US8476798B2
(en)
|
2008-11-28 |
2013-07-02 |
Pratt & Whitney Canada Corp. |
Tandem electric machine arrangement
|
|
WO2010091308A2
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
|
EP2421972A2
(en)
|
2009-04-24 |
2012-02-29 |
The Board of Regents of The University of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
|
|
GB2462940B8
(en)
*
|
2009-09-03 |
2012-03-28 |
Protean Holdings Corp |
Electric motor and electric generator.
|
|
US8749192B2
(en)
|
2009-09-03 |
2014-06-10 |
Protean Electric Limited |
Electric motor and electric generator
|
|
US20110110860A1
(en)
|
2009-11-02 |
2011-05-12 |
The Board Of Regents Of The University Of Texas System |
Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
|
|
WO2011085271A2
(en)
|
2010-01-08 |
2011-07-14 |
Isis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
|
US9574191B2
(en)
|
2010-02-03 |
2017-02-21 |
The Board Of Regents Of The University Of Texas System |
Selective inhibition of polyglutamine protein expression
|
|
EP3208347B1
(en)
|
2010-02-08 |
2019-08-14 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
EP3561060A1
(en)
|
2010-02-08 |
2019-10-30 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
US9127033B2
(en)
|
2010-04-28 |
2015-09-08 |
Isis Pharmaceuticals, Inc. |
5′ modified nucleosides and oligomeric compounds prepared therefrom
|
|
US9156873B2
(en)
|
2010-04-28 |
2015-10-13 |
Isis Pharmaceuticals, Inc. |
Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
|
|
EP2601204B1
(en)
|
2010-04-28 |
2016-09-07 |
Ionis Pharmaceuticals, Inc. |
Modified nucleosides and oligomeric compounds prepared therefrom
|
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
KR20180026798A
(en)
|
2010-04-29 |
2018-03-13 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Modulation of transthyretin expression
|
|
US8957200B2
(en)
|
2010-06-07 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
WO2011156202A1
(en)
|
2010-06-08 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
EP3031920B1
(en)
|
2010-07-19 |
2019-08-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dystrophia myotonica-protein kinase (dmpk) expression
|
|
JP5577506B2
(en)
|
2010-09-14 |
2014-08-27 |
ソーラテック コーポレイション |
Centrifugal pump device
|
|
FR2967310B1
(en)
|
2010-11-04 |
2013-08-02 |
Xap |
ELECTROMAGNETIC MOTOR WITHOUT BRUSH
|
|
CA2817960C
(en)
|
2010-11-17 |
2020-06-09 |
Isis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
WO2012109395A1
(en)
|
2011-02-08 |
2012-08-16 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
JP5969979B2
(en)
|
2011-03-28 |
2016-08-17 |
ソーラテック コーポレイション |
Rotation drive device and centrifugal pump device using the same
|
|
CA2831915C
(en)
|
2011-04-01 |
2021-01-12 |
Isis Pharmaceuticals, Inc. |
Modulation of signal transducer and activator of transcription 3 (stat3) expression
|
|
DE102011016336A1
(en)
|
2011-04-07 |
2012-10-11 |
Airbus Operations Gmbh |
High-lift system for an aircraft
|
|
CA2832972C
(en)
|
2011-04-13 |
2019-04-30 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
|
EA029137B1
(en)
|
2011-04-21 |
2018-02-28 |
Ионис Фармасьютикалз, Инк. |
Modulation of hepatitis b virus (hbv) expression
|
|
CN103547271A
(en)
|
2011-04-27 |
2014-01-29 |
Isis制药公司 |
Modulation of apolipoprotein CIII (APOCIII) expression
|
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
CA2838984A1
(en)
|
2011-06-10 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (klkb1) expression
|
|
EP2721156B1
(en)
|
2011-06-16 |
2016-12-21 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of fibroblast growth factor receptor 4 expression
|
|
WO2013003808A1
(en)
|
2011-06-29 |
2013-01-03 |
Isis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (klkb1) expression
|
|
EP3556859B1
(en)
|
2011-08-11 |
2021-04-07 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
|
EP3453761A1
(en)
|
2011-08-29 |
2019-03-13 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
US8865674B2
(en)
|
2011-09-20 |
2014-10-21 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of GCGR expression
|
|
BR112014009790A2
(en)
|
2011-10-25 |
2018-05-15 |
Isis Pharmaceuticals Inc |
compound for antisense modulation of gccr expression, its use and composition
|
|
EP3650544A1
(en)
|
2011-11-07 |
2020-05-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of tmprss6 expression
|
|
DK2794880T3
(en)
|
2011-12-22 |
2018-07-23 |
Ionis Pharmaceuticals Inc |
METHOD OF MODULATING METASTASE-ASSOCIATED-IN-LONG-ADENOCARCINOM TRANSCRIPT-1- (MALATE-1) EXPRESSION
|
|
EP2802674B1
(en)
|
2012-01-11 |
2020-12-16 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation of ikbkap splicing
|
|
WO2013120003A1
(en)
|
2012-02-08 |
2013-08-15 |
Isis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
|
US8837096B2
(en)
|
2012-03-13 |
2014-09-16 |
Thoratec Corporation |
Fault monitor for fault tolerant implantable pump
|
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
|
EP2850092B1
(en)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
|
WO2013159108A2
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
US9518261B2
(en)
|
2012-05-22 |
2016-12-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of enhancer RNA mediated gene expression
|
|
EP2855500B1
(en)
|
2012-05-24 |
2020-07-01 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein(a) expression
|
|
PL3461895T3
(en)
|
2012-06-25 |
2021-01-11 |
Ionis Pharmaceuticals, Inc. |
Modulation of ube3a-ats expression
|
|
EP2877579B1
(en)
|
2012-07-27 |
2019-12-18 |
Ionis Pharmaceuticals, Inc. |
Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
|
|
EP2885312B1
(en)
|
2012-08-15 |
2025-09-03 |
Ionis Pharmaceuticals, Inc. |
Method of preparing oligomeric compounds using modified capping protocols
|
|
US9993522B2
(en)
|
2012-09-18 |
2018-06-12 |
Uti Limited Partnership |
Treatment of pain by inhibition of USP5 de-ubiquitinase
|
|
US9175291B2
(en)
|
2012-10-11 |
2015-11-03 |
Isis Pharmaceuticals Inc. |
Modulation of androgen receptor expression
|
|
WO2014059364A1
(en)
|
2012-10-11 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Methods of treating kennedy's disease
|
|
WO2014059356A2
(en)
|
2012-10-12 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
|
EP4144845B1
(en)
|
2012-10-12 |
2024-04-24 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
|
DK2906696T4
(en)
|
2012-10-15 |
2023-02-27 |
Ionis Pharmaceuticals Inc |
METHODS OF MODULATING C9ORF72 EXPRESSION
|
|
MX365158B
(en)
|
2012-10-31 |
2019-05-24 |
Ionis Pharmaceuticals Inc |
Cancer treatment.
|
|
CN117126846A
(en)
|
2012-11-15 |
2023-11-28 |
罗氏创新中心哥本哈根有限公司 |
Oligonucleotide conjugates
|
|
DK2922955T3
(en)
|
2012-11-26 |
2019-05-13 |
Roche Innovation Ct Copenhagen As |
Compositions and Methods for Modulating FGFR3 Expression
|
|
US8968174B2
(en)
|
2013-01-16 |
2015-03-03 |
Thoratec Corporation |
Motor fault monitor for implantable blood pump
|
|
US9371826B2
(en)
|
2013-01-24 |
2016-06-21 |
Thoratec Corporation |
Impeller position compensation using field oriented control
|
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
|
CA2893801A1
(en)
|
2013-01-30 |
2014-08-07 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotide carbohydrate conjugates
|
|
CA2899924A1
(en)
|
2013-02-04 |
2014-08-07 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
|
KR102169899B1
(en)
|
2013-02-14 |
2020-10-26 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations
|
|
US9556873B2
(en)
|
2013-02-27 |
2017-01-31 |
Tc1 Llc |
Startup sequence for centrifugal pump with levitated impeller
|
|
US10398661B2
(en)
|
2013-02-28 |
2019-09-03 |
The Board Of Regents Of The University Of Texas System |
Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers
|
|
DE102013102194A1
(en)
*
|
2013-03-06 |
2014-09-11 |
Werner Eck |
Drive device for a moving in a fluid vehicle
|
|
WO2014153236A1
(en)
|
2013-03-14 |
2014-09-25 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating tau expression
|
|
US10052420B2
(en)
|
2013-04-30 |
2018-08-21 |
Tc1 Llc |
Heart beat identification and pump speed synchronization
|
|
DK2991656T3
(en)
|
2013-05-01 |
2020-03-23 |
Ionis Pharmaceuticals Inc |
COMPOSITIONS AND PROCEDURES FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
|
|
US9909124B2
(en)
|
2013-06-21 |
2018-03-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile
|
|
EP3564374A1
(en)
|
2013-06-21 |
2019-11-06 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation of target nucleic acids
|
|
SG11201510656PA
(en)
|
2013-06-27 |
2016-01-28 |
Roche Innovation Ct Copenhagen As |
Antisense oligomers and conjugates targeting pcsk9
|
|
RU2700244C2
(en)
|
2013-07-02 |
2019-09-13 |
Ионис Фармасьютикалз, Инк. |
Modulators of growth hormone receptor
|
|
TW202246503A
(en)
|
2013-07-19 |
2022-12-01 |
美商百健Ma公司 |
Compositions for modulating tau expression
|
|
US10435430B2
(en)
|
2013-07-31 |
2019-10-08 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
HRP20200250T1
(en)
|
2013-08-08 |
2020-05-29 |
The Scripps Research Institute |
SITE-SPECIFIC ENZYME MARKING OF NUCLEIC ACIDS AND IN VITRO IMPLEMENTATION OF NON-NATURAL NUCLEOTIDS
|
|
TW201536329A
(en)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
Compound and method for regulating the manifestation of dystrophic myotonic protein kinase (DMPK)
|
|
JP6652922B2
(en)
|
2013-08-28 |
2020-02-26 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
Regulation of prekallikrein (PKK) expression
|
|
US20160222389A1
(en)
|
2013-09-13 |
2016-08-04 |
Ionis Pharmaceuticals, Inc. |
Modulators of complement factor b
|
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
SG10201808903UA
(en)
|
2013-10-11 |
2018-11-29 |
Ionis Pharmaceuticals Inc |
Compositions for modulating c9orf72 expression
|
|
US9239345B2
(en)
|
2013-11-20 |
2016-01-19 |
Woodward, Inc. |
Controlling a motor with two or more Hall sensors
|
|
ES2797679T3
(en)
|
2013-12-02 |
2020-12-03 |
Ionis Pharmaceuticals Inc |
Antisense compounds and their uses
|
|
US20170037409A1
(en)
|
2013-12-24 |
2017-02-09 |
Ionis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
|
US10988030B2
(en)
|
2014-09-26 |
2021-04-27 |
Francis Xavier Gentile |
Electric motor, generator and battery combination
|
|
RU2019130898A
(en)
|
2014-03-19 |
2019-11-11 |
Ионис Фармасьютикалз, Инк. |
COMPOSITIONS FOR MODULATION OF ATAXIN 2 EXPRESSION
|
|
SG10201910844SA
(en)
|
2014-04-01 |
2020-01-30 |
Biogen Ma Inc |
Compositions for modulating sod-1 expression
|
|
TWI638047B
(en)
|
2014-04-09 |
2018-10-11 |
史基普研究協會 |
Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
|
|
WO2015164693A1
(en)
|
2014-04-24 |
2015-10-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
|
EP3137476B1
(en)
|
2014-04-28 |
2019-10-09 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
|
EP3137115B1
(en)
|
2014-05-01 |
2020-10-14 |
Ionis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
|
WO2015168532A2
(en)
|
2014-05-01 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating pkk expression
|
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
US9623161B2
(en)
|
2014-08-26 |
2017-04-18 |
Tc1 Llc |
Blood pump and method of suction detection
|
|
US10822369B2
(en)
|
2014-11-14 |
2020-11-03 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of proteins
|
|
US10364433B2
(en)
|
2014-11-14 |
2019-07-30 |
The Regents Of The University Of California |
Modulation of AGPAT5 expression
|
|
CN105634225B
(en)
*
|
2014-11-26 |
2020-10-09 |
德昌电机(深圳)有限公司 |
Brushless DC motor and electric power steering system using the same
|
|
US9517270B2
(en)
|
2014-12-08 |
2016-12-13 |
The Board Of Regents Of The University Of Texas System |
Lipocationic polymers and uses thereof
|
|
AU2015364508A1
(en)
|
2014-12-18 |
2017-07-06 |
Alnylam Pharmaceuticals, Inc. |
ReversirTM compounds
|
|
EP3256183B1
(en)
|
2015-02-11 |
2025-08-13 |
Tc1 Llc |
Heart beat identification and pump speed synchronization
|
|
US10371152B2
(en)
|
2015-02-12 |
2019-08-06 |
Tc1 Llc |
Alternating pump gaps
|
|
WO2016130944A1
(en)
|
2015-02-12 |
2016-08-18 |
Thoratec Corporation |
System and method for controlling the position of a levitated rotor
|
|
US10245361B2
(en)
|
2015-02-13 |
2019-04-02 |
Tc1 Llc |
Impeller suspension mechanism for heart pump
|
|
BR112017017178A2
(en)
|
2015-02-26 |
2018-04-03 |
Ionis Pharmaceuticals Inc |
p23h rhodopsin allele-specific modulators
|
|
US20180044673A1
(en)
|
2015-03-03 |
2018-02-15 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating mecp2 expression
|
|
EP4636085A3
(en)
|
2015-03-03 |
2026-01-07 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating mecp2 expression
|
|
AU2016285724A1
(en)
|
2015-06-29 |
2017-11-16 |
Ionis Pharmaceuticals, Inc. |
Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
|
|
AU2016294347B2
(en)
|
2015-07-10 |
2022-07-28 |
Ionis Pharmaceuticals, Inc. |
Modulators of diacyglycerol acyltransferase 2 (DGAT2)
|
|
EP3324980B1
(en)
|
2015-07-17 |
2021-11-10 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
|
DK3349802T3
(en)
|
2015-09-14 |
2021-10-11 |
Univ Texas |
Lipocationic dendrimers and uses thereof
|
|
RU2018113709A
(en)
|
2015-09-24 |
2019-10-30 |
Айонис Фармасьютикалз, Инк. |
KRAS EXPRESSION MODULATORS
|
|
US10117983B2
(en)
|
2015-11-16 |
2018-11-06 |
Tc1 Llc |
Pressure/flow characteristic modification of a centrifugal pump in a ventricular assist device
|
|
US11761007B2
(en)
|
2015-12-18 |
2023-09-19 |
The Scripps Research Institute |
Production of unnatural nucleotides using a CRISPR/Cas9 system
|
|
CN109414408B
(en)
|
2016-05-16 |
2022-03-29 |
得克萨斯州大学系统董事会 |
Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
|
|
US20190218257A1
(en)
|
2016-06-24 |
2019-07-18 |
The Scripps Research Institute |
Novel nucleoside triphosphate transporter and uses thereof
|
|
US11148819B2
(en)
|
2019-01-23 |
2021-10-19 |
H55 Sa |
Battery module for electrically-driven aircraft
|
|
US11063323B2
(en)
|
2019-01-23 |
2021-07-13 |
H55 Sa |
Battery module for electrically-driven aircraft
|
|
US10479223B2
(en)
|
2018-01-25 |
2019-11-19 |
H55 Sa |
Construction and operation of electric or hybrid aircraft
|
|
US11065979B1
(en)
|
2017-04-05 |
2021-07-20 |
H55 Sa |
Aircraft monitoring system and method for electric or hybrid aircrafts
|
|
US10854866B2
(en)
|
2019-04-08 |
2020-12-01 |
H55 Sa |
Power supply storage and fire management in electrically-driven aircraft
|
|
US12409756B2
(en)
|
2017-04-05 |
2025-09-09 |
H55 Sa |
Aircraft monitoring system and method for electric or hybrid aircrafts
|
|
US10807729B2
(en)
*
|
2017-05-17 |
2020-10-20 |
General Electric Company |
Propulsion system for an aircraft
|
|
WO2019014262A1
(en)
|
2017-07-11 |
2019-01-17 |
The Scripps Research Institute |
Incorporation of unnatural nucleotides and methods of use in vivo thereof
|
|
IL322312A
(en)
|
2017-08-03 |
2025-09-01 |
Synthorx Inc |
Cytokine conjugates for the treatment of proliferative and infectious diseases
|
|
CA3091857A1
(en)
|
2018-02-26 |
2019-08-29 |
Synthorx, Inc. |
Il-15 conjugates and uses thereof
|
|
MX2020011570A
(en)
|
2018-05-07 |
2020-11-24 |
Alnylam Pharmaceuticals Inc |
Extrahepatic delivery.
|
|
AU2019350765A1
(en)
|
2018-09-28 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated ocular diseases
|
|
CA3127689A1
(en)
|
2019-02-06 |
2020-08-13 |
Synthorx, Inc. |
Il-2 conjugates and methods of use thereof
|
|
JP7667074B2
(en)
|
2019-03-29 |
2025-04-22 |
田辺三菱製薬株式会社 |
Compounds, methods and pharmaceutical compositions for modulating DUX4 expression
|
|
EP3969052A1
(en)
|
2019-05-17 |
2022-03-23 |
Alnylam Pharmaceuticals Inc. |
Oral delivery of oligonucleotides
|
|
KR20220047598A
(en)
|
2019-08-15 |
2022-04-18 |
신톡스, 인크. |
Immuno-oncology Combination Therapy Using IL-2 Conjugates
|
|
CA3148135A1
(en)
|
2019-08-23 |
2021-03-04 |
Carolina E. CAFFARO |
Il-15 conjugates and uses thereof
|
|
CN114746122A
(en)
|
2019-09-10 |
2022-07-12 |
新索思股份有限公司 |
IL-2 conjugates and methods of use to treat autoimmune diseases
|
|
TWI891672B
(en)
|
2019-11-04 |
2025-08-01 |
美商欣爍克斯公司 |
Interleukin 10 conjugates and uses thereof
|
|
CA3160329A1
(en)
|
2019-11-06 |
2021-05-14 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
|
EP4055165A1
(en)
|
2019-11-06 |
2022-09-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
EP4151237A4
(en)
|
2020-05-12 |
2024-08-14 |
Mitsubishi Tanabe Pharma Corporation |
COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING ATAXY-3 EXPRESSION
|
|
MX2022016254A
(en)
|
2020-06-25 |
2023-04-11 |
Synthorx Inc |
Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodies.
|
|
US20230257745A1
(en)
|
2020-07-10 |
2023-08-17 |
Alnylam Pharmaceuticals, Inc. |
Circular siRNAs
|
|
TW202228785A
(en)
|
2020-10-09 |
2022-08-01 |
美商欣爍克斯公司 |
Immuno oncology combination therapy with il-2 conjugates and pembrolizumab
|
|
AU2021356610A1
(en)
|
2020-10-09 |
2023-06-15 |
Synthorx, Inc. |
Immuno oncology therapies with il-2 conjugates
|
|
CA3196205A1
(en)
|
2020-10-23 |
2022-04-28 |
Floyd E. Romesberg |
Reverse transcription of polynucleotides comprising unnatural nucleotides
|
|
CR20230308A
(en)
|
2020-12-11 |
2023-09-08 |
Civi Biopharma Inc |
ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETTING PCSK9
|
|
WO2022147223A2
(en)
|
2020-12-31 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
2'-modified nucleoside based oligonucleotide prodrugs
|
|
AU2021411579A1
(en)
|
2020-12-31 |
2023-07-13 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
|
EP4291243A1
(en)
|
2021-02-12 |
2023-12-20 |
Synthorx, Inc. |
Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
|
|
TW202245843A
(en)
|
2021-02-12 |
2022-12-01 |
美商欣爍克斯公司 |
Skin cancer combination therapy with il-2 conjugates and cemiplimab
|
|
IL307298A
(en)
|
2021-03-31 |
2023-11-01 |
Entrada Therapeutics Inc |
Cyclic cell penetrating peptides
|
|
KR20240012425A
(en)
|
2021-05-10 |
2024-01-29 |
엔트라다 테라퓨틱스, 인크. |
Compositions and methods for intracellular therapeutics
|
|
WO2022240721A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
|
|
US20250051780A1
(en)
|
2021-05-10 |
2025-02-13 |
Entrada Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING
|
|
US11682997B2
(en)
|
2021-05-17 |
2023-06-20 |
Hitachi Astemo Americas, Inc. |
Rotary electric machine with selectable coil control
|
|
TW202313117A
(en)
|
2021-06-03 |
2023-04-01 |
美商欣爍克斯公司 |
Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
|
|
KR20240038967A
(en)
|
2021-06-23 |
2024-03-26 |
엔트라다 테라퓨틱스, 인크. |
Antisense compounds and methods for targeting CUG repeats
|
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
|
MX2024000981A
(en)
|
2021-07-21 |
2024-02-12 |
Alnylam Pharmaceuticals Inc |
Metabolic disorder-associated target gene irna compositions and methods of use thereof.
|
|
KR20240082344A
(en)
|
2021-09-01 |
2024-06-10 |
엔트라다 테라퓨틱스, 인크. |
Compounds and methods for skipping exon 44 in Duchenne muscular dystrophy
|
|
KR20240101590A9
(en)
|
2021-10-15 |
2025-12-10 |
알닐람 파마슈티칼스 인코포레이티드 |
Extrahepatic delivery IRNA composition and method of using the same
|
|
US20250019702A1
(en)
|
2021-11-10 |
2025-01-16 |
University Of Rochester |
Gata4-targeted therapeutics for treatment of cardiac hypertrophy
|
|
CA3237770A1
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Antisense oligonucleotides for modifying protein expression
|
|
JP2025501682A
(en)
|
2021-12-03 |
2025-01-23 |
クラリス コーポレーション |
Gapmer antisense oligonucleotides with modified backbone chemistry - Patent Application 20070229933
|
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
|
JP2025516680A
(en)
|
2022-05-13 |
2025-05-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Single-stranded loop oligonucleotide
|
|
WO2024006999A2
(en)
|
2022-06-30 |
2024-01-04 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
|
JP2025530741A
(en)
|
2022-08-29 |
2025-09-17 |
ユニヴァーシティ オヴ ロチェスター |
Antisense oligonucleotide-based antifibrotic therapeutic agents
|
|
JP2025532985A
(en)
|
2022-09-30 |
2025-10-03 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Modified double-stranded RNA agents
|
|
WO2024136899A1
(en)
|
2022-12-21 |
2024-06-27 |
Synthorx, Inc. |
Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
|
|
CN120813691A
(en)
|
2023-02-09 |
2025-10-17 |
阿尔尼拉姆医药品有限公司 |
REVERSIR molecules and methods of use thereof
|
|
WO2024196937A1
(en)
|
2023-03-20 |
2024-09-26 |
Synthorx, Inc. |
Cancer therapy with il-2 peg conjugates
|
|
WO2024216155A1
(en)
|
2023-04-12 |
2024-10-17 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery of double-stranded rna agents
|
|
WO2024238385A2
(en)
|
2023-05-12 |
2024-11-21 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
|
WO2025064660A2
(en)
|
2023-09-21 |
2025-03-27 |
Alnylam Pharmaceuticals, Inc. |
Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
|
|
WO2025080939A1
(en)
|
2023-10-13 |
2025-04-17 |
Ultragenyx Pharmaceutical, Inc. |
Compositions and methods for treating conditions associated with cartilage oligomeric matrix protein (comp) mutations
|
|
WO2025128853A2
(en)
|
2023-12-13 |
2025-06-19 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for treating conditions associated with ube3a overexpression
|
|
WO2025158385A1
(en)
|
2024-01-25 |
2025-07-31 |
Genzyme Corporation |
Pegylated il-2 for suppressing adaptive immune response to gene therapy
|
|
WO2025207517A2
(en)
|
2024-03-25 |
2025-10-02 |
Synthorx, Inc. |
Synthetic trna synthetases and cells comprising synthetic molecules for production of polypeptides
|
|
GB202404290D0
(en)
|
2024-03-26 |
2024-05-08 |
Senisca Ltd |
Novel oligoncleotides
|